Therapeutic potential of the SARMs

Revisiting the androgen receptor for drug discovery

Scott Segal, Ramesh Narayanan, James T. Dalton

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Selective androgen receptor modulators (SARMS) bind to the androgen receptor and demonstrate anabolic activity in a variety of tissues; however, unlike testosterone and other anabolic steroids, these nonsteroidal agents are able to induce bone and muscle growth, as well as shrinking the prostate. The potential of SARMS is to maximise the positive attributes of steroidal androgens as well as minimising negative effects, thus providing therapeutic opportunities in a variety of diseases, including muscle wasting associated with burns, cancer, end-stage renal disease, osteoporosis, frailty and hypogonadism. This review summarises androgen physiolology, the current status of the R&D of SARMS and potential therapeutic indications for this emerging class of drugs.

Original languageEnglish (US)
Pages (from-to)377-387
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume15
Issue number4
DOIs
StatePublished - Apr 1 2006
Externally publishedYes

Fingerprint

Androgen Receptors
Drug Discovery
Androgens
Testosterone Congeners
Muscles
Hypogonadism
Bone Development
Therapeutics
Burns
Osteoporosis
Chronic Kidney Failure
Testosterone
Prostate
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Therapeutic potential of the SARMs : Revisiting the androgen receptor for drug discovery. / Segal, Scott; Narayanan, Ramesh; Dalton, James T.

In: Expert Opinion on Investigational Drugs, Vol. 15, No. 4, 01.04.2006, p. 377-387.

Research output: Contribution to journalReview article

@article{3f184e7602604efc90b39af3bafddeae,
title = "Therapeutic potential of the SARMs: Revisiting the androgen receptor for drug discovery",
abstract = "Selective androgen receptor modulators (SARMS) bind to the androgen receptor and demonstrate anabolic activity in a variety of tissues; however, unlike testosterone and other anabolic steroids, these nonsteroidal agents are able to induce bone and muscle growth, as well as shrinking the prostate. The potential of SARMS is to maximise the positive attributes of steroidal androgens as well as minimising negative effects, thus providing therapeutic opportunities in a variety of diseases, including muscle wasting associated with burns, cancer, end-stage renal disease, osteoporosis, frailty and hypogonadism. This review summarises androgen physiolology, the current status of the R&D of SARMS and potential therapeutic indications for this emerging class of drugs.",
author = "Scott Segal and Ramesh Narayanan and Dalton, {James T.}",
year = "2006",
month = "4",
day = "1",
doi = "10.1517/13543784.15.4.377",
language = "English (US)",
volume = "15",
pages = "377--387",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Therapeutic potential of the SARMs

T2 - Revisiting the androgen receptor for drug discovery

AU - Segal, Scott

AU - Narayanan, Ramesh

AU - Dalton, James T.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Selective androgen receptor modulators (SARMS) bind to the androgen receptor and demonstrate anabolic activity in a variety of tissues; however, unlike testosterone and other anabolic steroids, these nonsteroidal agents are able to induce bone and muscle growth, as well as shrinking the prostate. The potential of SARMS is to maximise the positive attributes of steroidal androgens as well as minimising negative effects, thus providing therapeutic opportunities in a variety of diseases, including muscle wasting associated with burns, cancer, end-stage renal disease, osteoporosis, frailty and hypogonadism. This review summarises androgen physiolology, the current status of the R&D of SARMS and potential therapeutic indications for this emerging class of drugs.

AB - Selective androgen receptor modulators (SARMS) bind to the androgen receptor and demonstrate anabolic activity in a variety of tissues; however, unlike testosterone and other anabolic steroids, these nonsteroidal agents are able to induce bone and muscle growth, as well as shrinking the prostate. The potential of SARMS is to maximise the positive attributes of steroidal androgens as well as minimising negative effects, thus providing therapeutic opportunities in a variety of diseases, including muscle wasting associated with burns, cancer, end-stage renal disease, osteoporosis, frailty and hypogonadism. This review summarises androgen physiolology, the current status of the R&D of SARMS and potential therapeutic indications for this emerging class of drugs.

UR - http://www.scopus.com/inward/record.url?scp=33645703903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645703903&partnerID=8YFLogxK

U2 - 10.1517/13543784.15.4.377

DO - 10.1517/13543784.15.4.377

M3 - Review article

VL - 15

SP - 377

EP - 387

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 4

ER -